A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Public ClinicalTrials.gov record NCT01453205. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for Autologous Stem Cell Transplant (ASCT), has superior efficacy compared to rituximab in the same population.
Study identification
- NCT ID
- NCT01453205
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 187 participants
Conditions and interventions
Conditions
Interventions
- MEDI-551 2 mg/kg Drug
- Rituximab Drug
- ICE Drug
- DHAP Drug
- Autologous Stem Cell Transplant (ASCT) Procedure
- MEDI-551 4 mg/kg Drug
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2012 (Actual)
- Primary completion
- Jul 11, 2016 (Actual)
- Completion
- Jul 11, 2016 (Actual)
- Last update posted
- Mar 12, 2018
2012 – 2016
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35061 | — |
| Research Site | Burbank | California | 91501 | — |
| Research Site | Palm Springs | California | 92262 | — |
| Research Site | Sylmar | California | 91342 | — |
| Research Site | Atlanta | Georgia | 30342 | — |
| Research Site | Westwood | Kansas | 66205 | — |
| Research Site | Hazard | Kentucky | 41701 | — |
| Research Site | Lafayette | Louisiana | 70503 | — |
| Research Site | Shreveport | Louisiana | 71103 | — |
| Research Site | Baltimore | Maryland | 21215 | — |
| Research Site | Minneapolis | Minnesota | 55455 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | Kansas City | Missouri | 66160 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | The Bronx | New York | 10466 | — |
| Research Site | Fargo | North Dakota | 58102 | — |
| Research Site | Dayton | Ohio | 45403 | — |
| Research Site | Newark | Ohio | 43055 | — |
| Research Site | Sylvania | Ohio | 43560 | — |
| Research Site | Hershey | Pennsylvania | 17033 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Knoxville | Tennessee | 37909 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Lubbock | Texas | 79410 | — |
| Research Site | Morgantown | West Virginia | 26505 | — |
| Research Site | Milwaukee | Wisconsin | 53266 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01453205, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2018 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01453205 live on ClinicalTrials.gov.